Bayer has awarded grants totaling more than $2 million to 16 recipients across eight countries as part of its Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers from the Children's Hospital of Philadelphia and Uniformed Services University of the Health Sciences in Maryland are among the winners. Grant recipients were announced last night during a reception at the International Society on Thrombosis and Hemostasis (ISTH) 2017 Congress, Berlin, Germany. The BHAP grants will support research into a broad range of projects, including anxiety among female carriers of hemophilia, FVIII splicing-switching molecules for tailored hemophilia A therapies, and the assessment of therapeutic relationships in hemophilia care. The U.S. BHAP winners are:
The BHAP award recipients are selected by a global panel of hemophilia clinicians, researchers and caregivers. To date, BHAP has awarded more than 280 grants, totaling more than $33 million, to researchers and caregivers from 32 countries around the world and contributed to more than 400 publications, poster presentations and other scientific communications by awardees. To learn more about BHAP, visit the
website
.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.